Cambrex's Strategic Collaboration with Eli Lilly
Cambrex, a key player in the global contract development and manufacturing organization (CDMO) sector, has announced an exciting new partnership with Eli Lilly and Company to enhance support for biotech collaborators. Through this agreement, Cambrex aims to provide accelerated access to essential clinical development capabilities, enabling faster product development in the competitive biotech landscape.
About the Collaboration with Lilly
This collaboration centers on Cambrex's partnership with Lilly's external innovation arm, Lilly Catalyze360. This initiative focuses on empowering biotech companies to bring their innovative concepts to fruition by providing comprehensive support in drug substance and product manufacturing, along with analytical services and R&D expertise. The alliance signifies a pivotal step in synergizing resources and expertise to foster accelerated development timelines.
Supporting Biotech Collaborators
Brandon Fincher, President of Early Stage Development & Testing at Cambrex, expressed enthusiasm about the partnership, stating, "We are excited to support Lilly's mission to enable external biotech collaborators to expedite their product development. Our Longmont facility offers all services required to advance early stage small molecules into the clinic with speed, flexibility, and scientific excellence." This statement highlights Cambrex's commitment to driving successful outcomes for Lilly's biotech partners.
Focus on Innovation and Efficiency
As part of this strategic agreement, Cambrex's Longmont facility will play a central role in supporting early-stage drug developers. This site specializes in the intricate process of investigational new drug development, covering everything from process and drug substance manufacturing to formulation development and full analytical testing. Cambrex's capabilities ensure that collaborators receive the comprehensive support needed to succeed in today's challenging biotech landscape.
About Cambrex
With a rich history of over 40 years, Cambrex stands out as a premier CDMO, offering a wide array of drug substance development and manufacturing services throughout the drug lifecycle. The company operates with a dedicated team of 2,000 professionals who provide specialized technologies and expertise tailored to meet the diverse needs of its global clientele across North America and Europe.
Commitment to Excellence
Cambrex prides itself on its advanced technological capabilities, which include continuous flow manufacturing, controlled substances expertise, and high-potency APIs. The organization is deeply invested in ensuring that emerging medicines advance effectively through its extensive network and specialized services. Cambrex's commitment to quality and innovation solidifies its reputation as a leader in the contract manufacturing industry.
Frequently Asked Questions
What is the purpose of Cambrex's collaboration with Lilly?
The collaboration aims to provide accelerated clinical development support for Lilly's biotech partners, enhancing their capabilities in bringing innovative drugs to market.
Where will the primary services of this collaboration be hosted?
The primary services will be hosted at Cambrex's Longmont facility, which specializes in early development of investigational new drugs.
What types of support does Cambrex offer to biotech companies?
Cambrex offers a full range of services including drug substance and product manufacturing, analytical services, and research and development expertise to support biotech companies.
How long has Cambrex been operating in the industry?
Cambrex has over 40 years of experience in the contract development and manufacturing sector, building a strong reputation in the industry.
What specialized technologies does Cambrex provide?
The company provides specialized drug substance technologies including continuous flow processes, material characterization, and the handling of highly potent APIs.
